Abstract Number: 2640 • 2015 ACR/ARHP Annual Meeting
Factors Influencing Treatment Adjustments in RA Patients – Biologic DMARD Treatment Start and Options
Background/Purpose: Current recommendations for pharmacologic management of rheumatoid arthritis (RA) advise dose titration or switching treatment if goals of remission or low disease activity are…Abstract Number: 549 • 2015 ACR/ARHP Annual Meeting
Calprotectin (MRP8/MRP14), a Major Leukocyte Protein, Is Highly Associated to Ultrasound Detected Synovitis and Is Responsive to Biologic Treatment
Background/Purpose: Calprotectin (MRP8/MRP14, S100A8/A9) is a protein abundant in cytosol of granulocytes and monocytes/macrophages and released during cell activation. It reflects clinical disease activity in…Abstract Number: 2641 • 2015 ACR/ARHP Annual Meeting
Correlation of Rheumatologists’ Perceptions of RA Severity with Observed Disease Activity, Patient Impact and Treatment Patterns
Background/Purpose: Efforts have been made in recent years to standardize the clinical assessment of RA patients with increased focus on objective measures, such as the…Abstract Number: 582 • 2015 ACR/ARHP Annual Meeting
Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Background/Purpose: Last years, biological dose tapering in patients with inflammatory diseases has become a routine clinical practice. Since 2011 we are applying a dose reduction…Abstract Number: 2667 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment
Background/Purpose: Despite an increasing armamentarium of efficacious treatments for Rheumatoid Arthritis (RA), sustained remission remains an unrealistic expectation for many patients, with most experiencing ongoing…Abstract Number: 590 • 2015 ACR/ARHP Annual Meeting
Expression Levels of Selected Genes May Predict Response to TNF Alpha Blockers or Rituximab in the Individual Rheumatoid Arthritis Patient
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a variety of therapeutic options however tools to predict individual patients' response are limited. The purpose of this…Abstract Number: 2746 • 2015 ACR/ARHP Annual Meeting
Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients
Background/Purpose: The options for treatment of rheumatic diseases is constantly growing. Tocilizumab (TCZ) is an anti-interleukin 6 receptor monoclonal antibody indicated for the treatment of severe…Abstract Number: 689 • 2015 ACR/ARHP Annual Meeting
Are Individual or Country Level Socio-Economic Determinants Related to Disease Activity and Self-Reported Physical Function in Patients with Spondyloarthritis – Results from Multi-National Cross-Sectional Study Comospa
Background/Purpose: In RA, previous studies observed inequalities across countries as well as individual level socio-economic factors, and unequal uptake of biologic DMARDs (bDMARDs) played an…Abstract Number: 3110 • 2015 ACR/ARHP Annual Meeting
In the Multicenter Randomized Controlled Rotation or Change Trial, a Non-TNF Targeted Therapy Has a Higher Efficacy Than a Second Anti-TNF at 3, 6 and 12 Months
Background/Purpose: As many as one third of patients show insufficient response to their first TNF inhibitor (TNF-insufficient response, TNF-IR). The lack of efficacy of one…Abstract Number: 977 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis which includes peripheral arthritis, enthesitis, dactylitis, and spondylitis manifestations. Ixekizumab, under investigation…Abstract Number: 3115 • 2015 ACR/ARHP Annual Meeting
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials
Background/Purpose: So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders.…Abstract Number: 1513 • 2015 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B-Infection in German Patients with Inflammatory Rheumatic Diseases Treated with Biologics – a Monocentric Analysis Involving 1107 Patients
Background/Purpose: Hepatitis B virus (HBV) reactivation is a common complication of immunosuppressive treatment in countries with a high prevalence of HBV infection. Biologics – and…Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting
Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…Abstract Number: 301 • 2014 ACR/ARHP Annual Meeting
Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register
Background/Purpose JIA often continues into adult life and affects about 1 in 1,000 people of childbearing age. Little is known about the impact of JIA…Abstract Number: 2821 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety/Tolerability of Mavrilimumab, a Human GM-CSFRá Monoclonal Antibody in Patients with Rheumatoid Arthritis
Background/Purpose Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in RA pathogenesis via myeloid and granulocyte cell lineage activation. In a prior Phase 2a study (NCT01050998), mavrilimumab,…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 14
- Next Page »